Web Appendix
&
Online Data Supplement
Extended Methods Section
Sample Selection
We selected the analytic sample using the National Health and Nutrition Examination
Survey (NHANES) fasting subsample as the baseline dataset. Fasting status of 8 hours or more
was ascertained from the question “the time in hours between when the examinee last ate or
drank anything other than water and the time of the venipuncture” in the NHANES fasting
questionnaire. Tables 1 and 2 show the sample selection process. For example, in the first wave,
1999-2000 (Table 1), there were 956 individuals aged 20 or older who self-identified as nonMexican-American white in the fasting subsample. Of these, 66 fasted for less than 8 hours and
29 did not report fasting status. An additional 18 people had missing values in glucose levels,
followed by 10 people with missing values in HDL cholesterol, 10 people missing in blood
pressure, and 5 more missing in waist circumference. Thus, the final analytic sample used in the
analysis contains 818 people for this racial group (818 = 956 – [66 + 29 + 18 + 10 + 10 + 5]).
Similar procedure for the other racial groups is shown in Table 1 and further disaggregation by
sex is shown in Table 2.
Definitions
Table 1 of the primary paper defines the various components of the metabolic syndrome
(MetS), and patients with three or more components were defined as having the MetS. The only
cut-off that varies in the harmonized MetS definition is the cut-off for abdominal obesity, where
the recommended cut-offs are population- and country-specific (3). In the current analyses, we
imposed the U.S. cut-offs (11) on all NHANES respondents, although there might be some
argument to have used Sub-Saharan African (≥94 cm for males and ≥80 for females) and Central
and South American (≥90 cm for males and ≥80 for females) cut-offs for non-Hispanic blacks
and Hispanics, respectively. However, given the complexity, lack of standardization, and widevariation in self-reported race in the United States, we choose to use the country-specific cut-offs
for all individuals. Given that these cut-offs are the highest of all populations, our estimates for
abdominal obesity may be conservative but likely do not overestimate the true prevalence. The
number of subjects who meet each of the criteria for the metabolic syndrome by race, sex, and
year is shown in OnlineTable 3. These are the sample sizes used in the prevalence estimates, as
well as in the statistical analyses.
Statistical Analysis
We examined overall population trends in addition to trends by race and gender using
two methods. To visualize, track and compare the prevalence of MetS over time, we used age
standardization, sometimes referred to as age adjustment. It is a statistical method that applies
observed age-specific prevalence rates to a standard age distribution. It is used to compare two or
more populations at one point in time, or one population at two or more points in time by
eliminating the confounding effect of age when age is related to the outcome of interest, as is the
case with cardiovascular disease. In other words, this method estimates prevalence as if the
groups under consideration had exactly the same age structure. This age-adjusted estimate is a
counterfactual, and not the observed (or unadjusted, or crude) prevalence in the study
population. There are two methods of age standardization- direct and indirect. We used the direct
method, as recommended for the continuous NHANES, which utilizes that standard population is
the 2000 Census data. Specifically, we multiply the age-specific prevalence from the study
population by the proportion of people in that age group in the standard population, and summed
the results to get the age-adjusted estimate: age-adjusted prevalence = ∑𝑝
1 𝑝𝑝 ∗ 𝑝𝑝 , where pi is
the prevalence of the condition in the study population, and wi is the proportion of people in that
age group in the standard population
For the trend analysis, our primary outcome was the slope of change or rate of change per
year from survey wave 1 (1999-2000) to survey wave 6 (2009-2010). We examined year as both
a continuous and ordinal variable; however, results did not change between these two
specifications and only show continuous (trend) coefficients. We used two modeling strategies,
both of which were age-adjusted. First we estimated a logistic model, which modeled how likely
it is that an individual had MetS or any MetS component in a given year. Secondly, we used a
Poisson specification since the number of cases of MetS or any component is a count variable.
Prevalence is defined as the ratio of the number of cases over total population, thus the Poisson
regression models the log of cases using the total population as an offset. While a logistic model
estimates the odds of having MetS or any component at a point in time, a Poisson model yields
prevalence estimates for each period. When we control for age, we are then estimating the ageadjusted prevalence for each year, which enabled us to test for significant differences across
years. We examined the direction and significance level for both age-adjusted regression
specifications to confirm the existence (or lack of) a time-trend. The estimates were qualitatively
similar and thus only the results of the Poisson models are shown in the supplement for
parsimony, but we can provide the logistic results upon request.
Statistical analyses were performed with Stata 12.1 (StataCorp) using sample weights that
accounted for the complex sampling design and nonresponse as recommended by the NHANES
online statistical tutorial. Strata with a single sampling unit were centered at the overall mean. P
≤ 0.05 was accepted as significant. The NHANES examination sample weight was used for
blood pressure, HDL cholesterol, and waist circumference estimates. The morning fasting
sample weight was used for glucose, triglycerides, and MetS estimates.
Analytic Sample
Table 1. Sample Selection from the Fasting Subsample for People Aged 20 or Older by Race/Ethnicity and Year: NHANES
1999/2000 to 2009/2010
Survey
wave
Fasting
subsample
(1)
Fasting status
Missin
<8 h
g
(2)
Non-Mexican-American White
1999-1900
956
66
2001-2002
1322
93
2003-2004
1185
76
2005-2006
1148
104
2007-2008
1299
116
2009-2010
1366
93
Non-Mexican-American Black
1999-2000
429
70
2001-2002
478
58
2003-2004
445
47
2005-2006
527
47
2007-2008
580
84
2009-2010
514
44
Mexican-American
1999-2000
595
48
2001-2002
537
29
2003-2004
458
42
2005-2006
438
24
2007-2008
478
43
2009-2010
559
36
Missing values in:
Triglyceride
Blood
s
pressure
Final analytic sample
Glucos
e
HDL-C
(3)
(4)
(5)
(6)
(7)
(8)
N = (1) – Sum
([2]:[8])
29
25
10
23
28
15
18
19
30
21
17
21
10
9
8
9
4
10
0
3
0
3
0
1
10
31
49
31
27
32
5
34
27
19
32
25
818
1108
985
938
1075
1169
21
19
4
16
26
8
17
22
23
21
27
26
8
13
2
4
5
6
1
2
3
4
0
0
15
14
22
31
20
33
5
5
15
12
8
13
292
345
329
392
410
384
22
11
5
14
6
8
7
6
9
7
10
6
8
6
0
0
0
4
0
0
1
1
2
1
3
19
23
10
17
18
4
11
5
9
16
5
503
455
373
373
384
481
Waist circ.
Table 2. Sample Selection from the Fasting Subsample for People Aged 20 or Older by
Race/Ethnicity, Sex and Year: NHANES 1999/2000 to 2009/2010
Fasting
Fasting status
subsample
<8hrs Missing
(1)
(2)
(3)
Non-Mexican-American White
Survey wave
1999-00
2001-02
2003-04
2005-06
2007-08
2009-10
455
626
565
577
663
644
Glucose
(4)
HDL-C
(5)
27
33
34
45
68
46
11
13
6
13
16
8
6
10
10
11
6
9
5
2
0
1
2
2
39
60
42
59
48
47
18
12
4
10
12
7
12
9
20
10
11
12
5
7
8
8
2
8
190
234
205
253
276
248
34
25
21
27
40
24
9
12
2
9
12
5
6
14
7
9
16
13
5
6
1
0
2
2
239
244
240
274
304
266
36
33
26
20
44
20
12
7
2
7
14
3
11
8
16
12
11
13
3
7
1
4
3
4
1999-00
2001-02
2003-04
2005-06
2007-08
2009-10
273
255
231
206
233
257
22
15
24
13
25
16
10
6
1
5
5
4
1
1
4
5
3
2
3
2
0
0
0
2
1999-00
2001-02
2003-04
2005-06
2007-08
2009-10
322
282
227
232
245
302
26
14
18
11
18
20
12
5
4
9
1
4
6
5
5
2
7
4
5
4
0
0
0
2
1999-00
501
2001-02
696
2003-04
620
2005-06
571
2007-08
636
2009-10
722
Non-Mexican-American Black
1999-00
2001-02
2003-04
2005-06
2007-08
2009-10
1999-00
2001-02
2003-04
2005-06
2007-08
2009-10
Mexican-American
Missing values in:
Triglycerides Blood pressure
(6)
(7)
Males
0
0
0
1
0
1
Females
0
3
0
2
0
0
Males
0
0
1
4
0
0
Females
1
2
2
0
0
0
Males
0
0
1
1
1
1
Females
0
0
0
0
1
0
Final analytic sample
Waist circ
(8)
N= (1) – Sum((2):(8))
3
14
14
17
16
12
2
18
9
9
12
13
401
536
492
480
543
553
7
17
35
14
11
20
3
16
18
10
20
12
417
572
493
458
532
616
6
5
7
9
11
12
2
2
7
7
3
2
128
170
159
188
192
190
9
9
15
22
9
21
3
3
8
5
5
11
164
175
170
204
218
194
1
8
10
3
5
5
2
5
1
3
7
4
234
218
190
176
187
223
2
11
13
7
12
13
2
6
4
6
9
1
269
237
183
197
197
258
Table 3. Number of Subjects who Meet Each of the Criteria for the Metabolic Syndrome by
Race/Ethnicity, Sex, and Year: NHANES 1999-2010
Survey wave
MetS
Glucose
3+ comp >=110 mg/dL
Non-Mexican-American White
1999-00
2001-02
2003-04
2005-06
2007-08
2009-10
105
159
144
134
183
146
HDL-Ca
83
118
104
116
191
173
137
169
117
100
157
152
36
83
57
79
128
121
153
177
141
94
161
209
23
34
24
37
35
36
17
26
29
45
57
51
29
37
20
22
26
35
40
45
39
46
63
53
27
31
25
36
59
41
58
67
52
39
49
61
1999-00
2001-02
2003-04
2005-06
2007-08
2009-10
77
70
53
47
63
80
51
56
49
47
80
81
90
79
47
46
52
78
1999-00
2001-02
2003-04
2005-06
2007-08
2009-10
113
75
75
44
71
73
45
33
44
41
53
53
137
104
69
52
77
96
1999-00
117
2001-02
176
2003-04
141
2005-06
114
2007-08
155
2009-10
166
Non-Mexican-American Black
Triglycerides Blood pressure b
>=150 mg/dL
Males
142
213
191
167
207
142
Females
159
205
163
156
154
168
Waist circ c
166
219
197
182
179
173
159
241
243
243
284
283
143
223
157
139
172
159
227
340
318
296
342
407
63
80
63
87
70
87
47
51
48
79
71
76
66
67
62
79
85
69
113
124
133
151
174
155
101
80
70
51
51
67
94
76
78
62
71
103
99
64
74
38
45
58
185
163
156
142
148
189
Males
1999-00
2001-02
2003-04
2005-06
2007-08
2009-10
1999-00
2001-02
2003-04
2005-06
2007-08
2009-10
Mexican-American
a
b
21
34
34
38
34
34
Females
22
28
29
29
30
23
Males
109
91
80
80
78
98
Females
130
93
92
74
63
72
Males: HDL-C<40mg/dL; females: HDL-C <50 mg/dL
Mean systolic blood pressure ≤130 mm Hg and mean diastolic blood pressure ≥85 mm Hg
Males: 102 cm ≤ waist circumference < 200 cm; females: 88 cm ≤ waist circumference < 200
cm
c
Prevalence Estimates
Table 4: Age-Standardized Prevalence Estimates for the Total Population by Race and Year: NHANES 1999-2010
1999-2000
2001-2002
2003-2004
2005-2006
2007-2008
2009-2010
Metabolic
Syndrome
Non-Mex25.59% (21.93- 27.21% (24.88- 26.19% (22.46- 23.19% (19.67- 24.54% (20.45- 21.77% (18.83American White
29.25)
29.54)
29.92)
26.71)
28.63)
24.70)
Non-Mex22.00% (17.76- 23.99% (18.13- 20.58% (17.12- 20.60% (16.63- 22.14% (13.73- 22.71% (17.95American Black
26.24)
29.85)
24.03)
24.57)
30.55)
27.48)
32.60% (25.02- 33.59% (28.51- 31.80% (27.20- 28.03% (20.74- 32.28% (28.83- 31.87% (26.14Mexican-American
40.19)
38.67)
36.41)
35.32)
35.72)
37.60)
Waist
Circumference
Non-Mex43.58% (37.56- 48.02% (44.58- 54.15% (49.65- 54.01% (49.62- 52.67% (48.74- 54.87% (51.13American White
49.61)
51.46)
58.64)
58.40)
56.60)
58.61)
Non-Mex54.80% (49.97- 52.29% (47.09- 57.59% (52.85- 58.07% (53.26- 59.23% (53.26- 63.04% (58.02American Black
59.62)
57.49)
62.32)
62.88)
65.19)
68.06)
49.90% (44.17- 52.65% (47.67- 60.66% (53.13- 52.69% (47.10- 54.86% (48.16- 58.73% (54.73Mexican-American
55.63)
57.63)
68.20)
58.28)
61.55)
62.73)
Blood Pressure
Non-MexAmerican White
Non-MexAmerican Black
Mexican-American
Triglycerides
Non-MexAmerican White
Non-Mex-
30.53% (26.9334.13)
42.59% (35.7049.48)
36.34% (30.7541.93)
33.69% (30.1837.20)
44.27% (38.6149.93)
35.15% (30.1140.19)
29.77% (26.3033.25)
38.61% (32.5744.65)
32.22% (28.2936.14)
29.10% (25.7632.45)
41.27% (37.1445.40)
27.22% (21.2133.23)
22.30% (20.0924.51)
36.27% (28.8643.68)
25.01% (20.8129.21)
21.74% (18.0825.41)
35.83% (31.5040.16)
27.83% (23.7831.88)
35.14% (30.3239.96)
12.69% (8.75-
34.61% (31.9137.30)
19.46% (12.14-
33.13% (28.9237.35)
17.73% (13.54-
31.42% (27.5235.33)
16.39% (12.28-
30.14% (27.2733.01)
14.69% (9.03-
24.02% (20.8927.14)
14.03% (9.18-
ptrend
0.00
9
0.92
0.81
0.00
1
0.02
0.11
9
<
0.00
1
0.84
0.02
<
0.00
1
0.65
American Black
Mexican-American
HDL-C
Non-MexAmerican White
Non-MexAmerican Black
Mexican-American
Glucose
16.62)
43.37% (38.3348.41)
26.78)
39.29% (35.3943.18)
21.93)
44.38% (40.6648.09)
20.49)
38.43% (30.3446.53)
20.35)
34.88% (29.3640.41)
18.88)
35.73% (29.6241.84)
39.52% (33.0845.95)
28.38% (22.8433.92)
42.91% (38.5047.33)
33.76% (30.0737.45)
32.21% (27.7636.67)
38.76% (32.6744.86)
27.80% (24.0531.54)
20.89% (13.9027.88)
32.42% (24.3840.47)
21.36% (18.7623.96)
16.57% (11.6121.54)
29.06% (23.0835.04)
29.57% (24.3434.80)
18.59% (11.5925.59)
31.03% (25.4436.62)
29.63% (25.7233.53)
27.05% (21.4832.61)
34.50% (29.7339.27)
Non-MexAmerican White
Non-MexAmerican Black
12.27% (8.8715.67)
17.02% (10.0723.97)
14.74% (12.4617.01)
17.11% (11.7922.44)
13.09% (11.4414.73)
17.64% (13.2722.01)
16.93% (13.9219.93)
18.92% (14.0923.74)
21.43% (17.7525.11)
23.43% (15.4531.42)
18.78% (14.6922.88)
21.79% (18.2625.32)
Mexican-American
18.75% (14.2423.27)
22.62% (19.8625.38)
23.90% (17.2930.50)
26.73% (20.0133.46)
33.95% (30.1137.78)
29.81% (25.5934.02)
0.07
6
0.00
1
0.01
0.04
8
<
0.00
1
0.00
6
<
0.00
1
Table 5: Age-Standardized Prevalence Estimates for Males by Race and Year: NHANES 1999-2010
1999-2000
2001-2002
2003-2004
2005-2006
2007-2008
Metabolic
Syndrome
Non-Mex23.93% (17.91- 28.06% (24.03- 26.51% (20.81- 25.21% (21.13- 27.17% (23.81American white
29.94)
32.10)
32.21)
29.30)
30.54)
Non-Mex17.39% (11.29- 19.90% (12.56- 17.49% (11.62- 16.31% (9.9017.28% (6.34American black
23.49)
27.24)
23.37)
22.72)
28.22)
Mexican26.77% (21.03- 33.66% (24.38- 26.19% (16.42- 27.18% (18.57- 31.13% (26.91American
32.52)
42.95)
35.95)
35.79)
35.35)
Waist
Circumference
Non-Mex36.43% (29.51- 41.39% (36.17- 48.05% (42.98- 48.65% (44.66- 47.83% (43.08American white
43.35)
46.62)
53.12)
52.64)
52.57)
Non-Mex36.11% (27.79- 29.03% (20.26- 31.87% (23.63- 38.22% (30.22- 34.33% (26.11American black
44.44)
37.81)
40.12)
46.21)
42.54)
Mexican35.76% (30.51- 37.31% (30.20- 38.49% (27.74- 34.90% (24.91- 38.78% (32.72American
41.01)
44.42)
49.25)
44.89)
44.83)
Blood Pressure
Non-MexAmerican white
Non-MexAmerican black
MexicanAmerican
Triglycerides
Non-MexAmerican white
Non-MexAmerican black
MexicanAmerican
2009-2010
22.91% (17.3828.43)
18.99% (9.7528.22)
34.76% (27.2542.27)
ptrend
0.29
0.95
0.06
4
47.15% (41.0953.21)
43.09% (33.9752.21)
46.53% (37.7555.31)
0.02
4
0.17
9
0.09
7
33.50% (28.2938.72)
44.11% (36.3151.90)
38.96% (32.9344.99)
36.44% (30.0642.82)
49.40% (41.7057.11)
41.07% (32.4449.69)
34.91% (29.6140.21)
41.13% (34.7347.53)
29.26% (24.3534.18)
33.21% (29.2637.16)
43.29% (34.8251.77)
29.23% (21.5436.91)
23.48% (20.1126.85)
35.11% (25.8344.40)
29.69% (23.7835.60)
25.63% (21.2530.01)
39.42% (32.1446.71)
35.29% (29.1741.40)
<
0.00
1
0.09
9
0.32
6
36.65% (29.0544.24)
13.92% (7.0120.83)
45.07% (38.6051.55)
39.29% (33.9844.60)
23.68% (14.7632.60)
43.57% (36.9250.22)
37.27% (31.7642.79)
21.62% (12.9930.25)
42.31% (34.7949.83)
37.00% (32.0141.99)
19.02% (12.5325.52)
45.18% (36.2654.10)
36.51% (32.0740.96)
17.84% (9.9225.75)
37.52% (31.3643.68)
25.02% (19.8430.20)
18.96% (12.1025.81)
39.09% (32.3045.87)
0.00
2
0.74
5
0.80
4
HDL-C-C
Non-MexAmerican white
Non-MexAmerican black
MexicanAmerican
Glucose
Non-MexAmerican white
Non-MexAmerican black
MexicanAmerican
37.45% (29.8545.05)
22.21% (13.9130.50)
37.06% (30.4743.65)
32.88% (28.1737.60)
20.67% (14.3227.02)
33.05% (26.9839.13)
23.97% (17.0230.91)
11.61% (7.1116.12)
25.37% (14.5336.22)
21.62% (17.8225.42)
10.59% (6.2314.96)
26.49% (17.5235.46)
29.67% (25.2634.08)
12.19% (5.0819.29)
24.63% (14.2135.05)
28.00% (22.6633.34)
19.74% (11.4428.04)
31.44% (26.1536.74)
0.00
6
16.50% (11.8521.15)
15.43% (6.8224.03)
18.28% (14.2522.31)
14.54% (8.9220.16)
17.04% (14.5319.55)
18.88% (13.0724.68)
19.27% (14.8723.67)
20.92% (14.2327.61)
27.10% (21.9632.24)
26.15% (15.4136.89)
23.63% (17.8929.37)
25.17% (16.3633.98)
19.28% (17.2521.31)
29.50% (26.3432.66)
27.46% (19.6135.31)
27.57% (18.5836.56)
43.78% (37.7349.83)
39.18% (34.0144.35)
0.00
1
0.00
2
<
0.00
1
0.17
0.87
3
Table 6: Age-standardized prevalence estimates for Females by race/ethnicity and year: NHANES 1999-2010
1999-2000
2001-2002
2003-2004
2005-2006
Metabolic Syndrome
Non-Mex-American white 27.08% (23.30-30.85) 25.80% (22.60-29.00) 25.91% (20.17-31.66) 21.69% (16.72-26.65)
Non-Mex-American black 25.74% (19.53-31.95) 27.57% (20.89-34.26) 23.24% (16.66-29.81) 22.84% (16.58-29.09)
Mexican-American
37.62% (29.44-45.80) 33.36% (26.19-40.53) 37.54% (31.87-43.21) 26.94% (17.52-36.36)
Waist Circumference
Non-Mex-American white 50.15% (43.81-56.50) 54.39% (49.64-59.15) 60.00% (53.59-66.41) 59.01% (52.60-65.43)
Non-Mex-American black 69.88% (64.16-75.60) 71.86% (64.88-78.85) 79.00% (74.66-83.34) 72.42% (67.04-77.80)
Mexican-American
64.60% (57.56-71.64) 68.55% (60.20-76.90) 84.76% (79.29-90.23) 71.21% (62.80-79.62)
Blood Pressure
Non-Mex-American white 27.37% (24.10-30.63) 31.09% (27.88-34.29) 24.65% (21.25-28.06) 25.76% (20.63-30.89)
Non-Mex-American black 38.59% (28.99-48.19) 39.97% (34.64-45.30) 36.31% (28.32-44.31) 39.37% (32.93-45.81)
Mexican-American
33.16% (27.75-38.58) 30.62% (26.12-35.12) 33.86% (27.89-39.84) 23.65% (16.77-30.54)
Triglycerides
Non-Mex-American white 33.70% (27.68-39.72) 29.52% (26.80-32.25) 28.90% (23.86-33.93) 26.49% (22.85-30.13)
Non-Mex-American black 11.54% (8.59-14.49) 15.57% (7.49-23.66) 14.20% (9.07-19.32) 12.25% (8.28-16.22)
Mexican-American
40.67% (32.95-48.38) 33.95% (25.06-42.84) 44.89% (35.17-54.60) 28.81% (20.69-36.94)
HDL-C
Non-Mex-American white 41.42% (33.96-48.88) 34.28% (29.94-38.61) 31.71% (24.90-38.51) 21.41% (17.60-25.22)
Non-Mex-American black 31.15% (22.13-40.16) 42.34% (34.14-50.55) 29.20% (18.63-39.78) 21.20% (13.45-28.96)
Mexican-American
50.30% (45.23-55.38) 44.58% (37.03-52.13) 41.96% (32.96-50.96) 32.48% (24.43-40.52)
Glucose
Non-Mex-American white 8.70% (6.45-10.95)
11.25% (9.17-13.34)
8.99% (6.52-11.46) 14.92% (10.86-18.99)
Non-Mex-American black 18.73% (12.96-24.51) 19.86% (14.24-25.48) 16.31% (12.02-20.61) 16.90% (11.58-22.21)
Mexican-American
17.60% (11.92-23.27) 14.73% (9.52-19.94) 20.98% (11.66-30.30) 23.64% (20.05-27.22)
2007-2008
22.33% (16.52-28.13) 2
26.80% (17.88-35.72) 2
32.38% (25.20-39.56) 2
57.55% (50.93-64.18) 6
78.72% (72.76-84.68) 7
71.84% (63.08-80.60) 7
20.65% (17.19-24.11) 1
36.94% (26.73-47.14) 3
19.79% (15.85-23.72) 2
24.75% (20.37-29.14) 2
12.82% (8.05-17.59) 1
30.31% (22.29-38.32) 2
29.37% (22.37-36.38) 3
24.40% (16.48-32.32) 3
37.01% (29.65-44.38) 3
16.07% (11.32-20.83) 1
21.98% (14.85-29.11) 1
24.89% (17.58-32.21) 2
Table 7: List of Prescription Drugs as used in NHANES Data Files
Generic Drug Name
(corresponds to "rx drug" variable
in NHANES data files)
ACARBOSE
ACEBUTOLOL
ACEBUTOLOL
HYDROCHLORIDE
ALISKIREN
ALISKIREN;
HYDROCHLOROTHIAZIDE
ALISKIREN; VALSARTAN
AMILORIDE
AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE;
HYDROCHLOROTHI
AMILORIDE;
HYDROCHLOROTHIAZIDE
AMLODIPINE
AMLODIPINE BESYLATE
AMLODIPINE BESYLATE;
BENAZEPRIL HYDROCH
AMLODIPINE; ATORVASTATIN
AMLODIPINE; BENAZEPRIL
AMLODIPINE;
HYDROCHLOROTHIAZIDE;
VALSAR
AMLODIPINE; OLMESARTAN
AMLODIPINE; VALSARTAN
ANTIDIABETIC AGENTS UNSPECIFIED
ANTIHYPERLIPIDEMIC AGENTS
- UNSPECIFIED
ANTIHYPERTENSIVE AGENTS UNSPECIFIED
ANTIHYPERTENSIVE
COMBINATIONS - UNSPECI
ATENOLOL
ATENOLOL; CHLORTHALIDONE
ATORVASTATIN
ATORVASTATIN CALCIUM
BENAZEPRIL
BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE;
HDL-C
specific
Lipidmodifying
agent
Antihyperglyce
mic
X
Antihypertensi
ve
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
HYDROCHLOROTH
BENAZEPRIL;
HYDROCHLOROTHIAZIDE
BISOPROLOL
BISOPROLOL FUMARATE
BISOPROLOL FUMARATE;
HYDROCHLOROTHIAZIDE
BISOPROLOL;
HYDROCHLOROTHIAZIDE
BUMETANIDE
CANDESARTAN
CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL;
HYDROCHLOROTHIAZE
CANDESARTAN;
HYDROCHLOROTHIAZIDE
CAPTOPRIL
CAPTOPRIL;
HYDROCHLOROTHIAZIDE
CERIVASTATIN SODIUM
CHLORPROMAMIDE;
PHENFORMIN
CHLORPROPAMIDE
CHLORTHALIDONE
CHLORTHALIDONE; CLONIDINE
HYDROCHLORIDE
CHOLESTEROL-LOWERING
DRUG-UNSPECIFIED
CHOLESTYRAMINE
CLONIDINE
CLONIDINE HYDROCHLORIDE
COLESEVELAM
COLESTIPOL
COLESTIPOL HYDROCHLORIDE
DIABETES DRUG-UNSPECIFIED
DIURETIC-UNSPECIFIED
DIURETICS - UNSPECIFIED
ENALAPRIL
ENALAPRIL MALEATE
ENALAPRIL MALEATE;
HYDROCHLOROTHIAZIDE
ENALAPRIL;
HYDROCHLOROTHIAZIDE
EPROSARTAN;
HYDROCHLOROTHIAZIDE
EXENATIDE
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
EZETIMIBE
EZETIMIBE; SIMVASTATIN
FELODIPINE
FENOFIBRATE
FENOFIBRIC ACID
FLUVASTATIN
FLUVASTATIN SODIUM
FOSINOPRIL
FOSINOPRIL SODIUM
FOSINOPRIL;
HYDROCHLOROTHIAZIDE
FUROSEMIDE
GEMFIBROZIL
GLIMEPIRIDE
GLIMEPIRIDE; ROSIGLITAZONE
GLIPIZIDE
GLIPIZIDE; METFORMIN
GLYBURIDE
GLYBURIDE; METFORMIN
GLYBURIDE; METFORMIN
HYDROCHLORIDE
HIGH BLOOD PRESSURE
MEDICINE-UNSPECIFIED
HYDRALAZINE
HYDRALAZINE
HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE;
HYDROCHLOROT
HYDRALAZINE HYDROCHLORIDE;
HYDROCHLOROT
HYDRALAZINE;
HYDROCHLOROTHIAZIDE
HYDRALAZINE; ISOSORBIDE
DINITRATE
HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE;
IRBESARTAN
HYDROCHLOROTHIAZIDE;
LISINOPRIL
HYDROCHLOROTHIAZIDE;
LOSARTAN
HYDROCHLOROTHIAZIDE;
LOSARTAN POTASSIUM
HYDROCHLOROTHIAZIDE;
METHYLDOPA
HYDROCHLOROTHIAZIDE;
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
METOPROLOL
HYDROCHLOROTHIAZIDE; METOPROLOL
TARTRAT
HYDROCHLOROTHIAZIDE;
MOEXIPRIL
HYDROCHLOROTHIAZIDE; MOEXIPRIL
HYDROCHL
HYDROCHLOROTHIAZIDE;
OLMESARTAN
HYDROCHLOROTHIAZIDE; PROPRANOLOL
HYDROC
HYDROCHLOROTHIAZIDE;
QUINAPRIL
HYDROCHLOROTHIAZIDE;
QUINAPRIL HYDROCHL
HYDROCHLOROTHIAZIDE;
SPIRONOLACTONE
HYDROCHLOROTHIAZIDE;
TELMISARTAN
HYDROCHLOROTHIAZIDE;
TRIAMTERENE
HYDROCHLOROTHIAZIDE;
VALSARTAN
INSULIN
INSULIN ASPART
INSULIN ASPART; INSULIN
ASPART PROTAMINE
INSULIN DETEMIR
INSULIN GLARGINE
INSULIN GLULISINE
INSULIN INHALATION RAPID
ACTING
INSULIN ISOPHANE
INSULIN ISOPHANE; INSULIN
REGULAR
INSULIN LISPRO
INSULIN LISPRO; INSULIN
LISPRO PROTAMIN
INSULIN REGULAR
INSULIN ZINC
INSULIN ZINC EXTENDED
IRBESARTAN
ISOSORBIDE
ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE
ISOSORBIDE-UNSPECIFIED
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
LABETALOL
LABETALOL HYDROCHLORIDE
LOSARTAN
LOSARTAN POTASSIUM
LOVASTATIN
LOVASTATIN; NIACIN
METFORMIN
METFORMIN HYDROCHLORIDE
METFORMIN; PIOGLITAZONE
METFORMIN; ROSIGLITAZONE
METFORMIN; SITAGLIPTIN
METOLAZONE
METOPROLOL
METOPROLOL SUCCINATE
METOPROLOL TARTRATE
METOPROLOL-UNSPECIFIED
NADOLOL
NATEGLINIDE
NEBIVOLOL
NIACIN
NIACIN; SIMVASTATIN
NICARDIPINE
NICARDIPINE
HYDROCHLORIDE
NIFEDIPINE
NISOLDIPINE
OLMESARTAN
PINDOLOL
PIOGLITAZONE
PIOGLITAZONE
HYDROCHLORIDE
PRAMLINTIDE
PRAVASTATIN
PRAVASTATIN SODIUM
QUINAPRIL
QUINAPRIL HYDROCHLORIDE
RAMIPRIL
REPAGLINIDE
ROSIGLITAZONE
ROSIGLITAZONE MALEATE
ROSUVASTATIN
SAXAGLIPTIN
SIMVASTATIN
SITAGLIPTIN
TELMISARTAN
TORSEMIDE
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
TRIAMTERENE
VERAPAMIL
VERAPAMIL HYDROCHLORIDE
X
X
X